search
Company Information
USD
24.66
- (0.6%)
NASDAQ:MYGN, MYRIAD GENETICS, INC.
Industry: Diagnostics & Research
End of Day: 25 June 2024 GMT-4
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Address

320 Wakara Way

Classification

Sector

Healthcare

Industry Group

Medical Diagnostics & Research

Industry

Diagnostics & Research

Key Executives

Mr. Daniel K. Spiegelman
Director
Dr. Heiner Dreismann,PhD
Director
Mr. Paul M. Bisaro
Director
Mr. Paul J. Diaz
CEO/Director/President
Ms. S. Louise Phanstiel
Chairman of the Board/Director
Dr. Daniel M. Skovronsky, M.D.
Director
Mr. Samraat S. Raha
COO
Ms. Colleen F. Reitan
Director
Dr. Lee N. Newcomer, M.D.
Director
Ms. Rashmi Kumar
Director
Mr. Scott J. Leffler
CFO
Ms. Natalie Munk
Chief Accounting Officer
Mr. Mark Verratti
Other Executive Officer
Ms. Margaret Ancona
Other Executive Officer/Senior VP
Mr. Kevin Richard Haas
Chief Technology Officer
Ms. Pamela Wong
Chief Legal Officer
Mr. Dale Muzzey
Chief Scientific Officer
Ms. Shereen Solaiman
Other Executive Officer

Ownership

Institution Holdings

BlackRock Inc
14,658,349 (16.310%)
BlackRock Fund Advisors
10,569,504 (11.760%)
Vanguard Group Inc
9,954,233 (11.076%)
Camber Capital Management LLC
7,635,000 (8.495%)
Wellington Management Company LLP
7,219,706 (8.033%)
Wellington Management Group, LLP
7,219,706 (8.033%)
Camber Capital Management LP
7,000,000 (7.789%)
Glenview Capital Management LLC
5,283,982 (5.879%)
State Street Corporation
4,700,631 (5.230%)
Earnest Partners LLC
3,913,913 (4.355%)

Funds Holdings

iShares Core S&P Small-Cap ETF
6,037,332 (6.717%)
Vanguard Explorer Fund
3,450,725 (3.839%)
Vanguard Total Stock Market Index Fund
2,651,696 (2.950%)
Vanguard US Total Market Shares ETF
2,651,696 (2.950%)
Vanguard Small Cap Index
2,171,401 (2.416%)
EARNEST Partners Smid Cap Core Fund
2,093,265 (2.329%)
iShares Russell 2000 ETF
1,964,338 (2.186%)
SPDR® S&P Biotech ETF
1,609,598 (1.791%)
Artisan Non-U.S. Small-Mid Growth
1,529,799 (1.702%)
Artisan International Small-Mid Fund
1,529,799 (1.702%)

Details

Overview Company Info Key Ratios Income Balance Sheet Cash Flow
Make Smart Investment Choices